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Abstract
Background  and  objectives:  the  medications  used  according  to  the  recommendation  of  the
World Health  Organization  do  not  promote  pain  relief  in  a  number  of  patients  with  cancer
pain. The  aim  of  this  study  was  to  evaluate  the  use  of  morphine  as  ﬁrst  medication  for  the
treatment of  moderate  cancer  pain  in  patients  with  advanced  and/or  metastatic  disease,  as  an
option to  the  recommendations  of  the  World  Health  Organization  analgesic  ladder.
Method:  sixty  patients  without  opioid  therapy,  with  ≥18  years  of  age,  were  randomized  into  two
groups. G1  patients  received  medication  according  to  the  analgesic  ladder  and  started  treat-
ment with  non-opioids  in  the  ﬁrst,  weak  opioids  in  the  second,  and  strong  opioids  in  the  third
step; G2  patients  received  morphine  as  ﬁrst  analgesic  medication.  The  efﬁcacy  and  tolerability
of initial  use  of  morphine  were  evaluated  every  two  weeks  for  three  months.
Results: the  groups  were  similar  with  respect  to  demographic  data.  There  was  no  signiﬁcant
difference between  the  groups  regarding  pain  intensity,  quality  of  life,  physical  capacity,  sat-
isfaction with  treatment,  need  for  complementation  and  dose  of  morphine.  In  G1  there  was  a
higher incidence  of  nausea  (p  =  0.0088),  drowsiness  (p  =  0.0005),  constipation  (p  =  0.0071)  and
dizziness (p  =  0.0376)  in  the  second  visit  and  drowsiness  (p  =  0.05)  in  the  third.
Conclusions:  the  use  of  morphine  as  ﬁrst  medication  for  pain  treatment  did  not  promote  bet-
ter analgesic  effect  than  the  ladder  recommended  by  World  Health  Organization,  with  higher
incidence of  adverse  effects.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
PALAVRAS-CHAVE
Dor  oncológica;
Morﬁna  como  primeiro  medicamento  para  tratamento  da  dor  de  câncerAnalgesia;
Morﬁna
Resumo
Justiﬁcativa  e  objetivos:  Os  medicamentos  usados  segundo  a  recomendac¸ão  da  Organizac¸ão
Mundial de  Saúde  (OMS)  não  promovem  alívio  da  dor  de  uma  parcela  dos  pacientes  com  dor
oncológica.  O  objetivo  deste  estudo  foi  avaliar  o  uso  de  morﬁna  como  primeiro  medicamento
para o  tratamento  da  dor  oncológica  moderada,  em  pacientes  com  doenc¸a  avanc¸ada  e/ou
metástases,  como  opc¸ão às  recomendac¸ões  da  escada  analgésica  preconizada  pela  OMS.
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E-mail: riokoks.dcir@epm.br (R.K. Sakata).
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Método:  Sessenta  pacientes  sem  terapia  com  opioide,  com  idade  maior  ou  igual  a  18  anos,
foram distribuídos  aleatoriamente  em  dois  grupos.  Os  pacientes  do  G1  receberam  medicamentos
segundo a  escada  analgésica  e  iniciaram  o  tratamento  com  não  opioide  no  primeiro  degrau,
opioide fraco  no  segundo  e  opioide  potente  no  terceiro;  os  do  G2  receberam  morﬁna  como
primeiro  medicamento  analgésico.  Foram  avaliadas  a  eﬁcácia  e  a  tolerabilidade  do  uso  inicial
de morﬁna,  a  cada  duas  semanas  durante  três  meses.
Resultados:  Os  grupos  foram  semelhantes  quanto  aos  dados  demográﬁcos.  Não  houve  diferenc¸a
signiﬁcante  entre  os  grupos  quanto  à  intensidade  da  dor,  qualidade  de  vida,  capacidade  física,
satisfac¸ão com  o  tratamento,  necessidade  de  complementac¸ão  e  dose  de  morﬁna  usada.  No  G1
houve maior  incidência  de  náusea  (p  =  0,0088),  sonolência  (p  =  0,0005),  constipac¸ão  (p  =  0,0071)
e tontura  (p  =  0,0376)  na  segunda  consulta  e  para  sonolência  (p  =  0,05)  na  terceira.
Conclusões:  O  uso  de  morﬁna  como  primeiro  medicamento  para  tratamento  da  dor  não  pro-
moveu melhor  efeito  analgésico  do  que  a  escada  preconizada  pela  OMS  e  houve  maior  incidência
de efeitos  adversos.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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logue  scale  (VAS),  quality  of  life  every  four  weeks  through
the  brief  questionnaire  of  quality  of  life  of  the  WHO,15 sat-Introduction
The  prevalence  of  cancer  has  increased,  with  an  estimated
projection  for  2020  of  17  million  new  cases.1 This  means  that
there  will  be  an  increase  in  individuals  with  pain  caused  by
the  disease  and  by  treatment.2
The  World  Health  Organization  (WHO)  developed  the
analgesic  ladder  as  a  guideline  for  the  treatment  of
cancer  pain  and  recommended  the  use  of  nonsteroid  anti-
inﬂammatory  drugs  (NSAIDs)  for  mild  pain  on  the  ﬁrst,  weak
opioids  for  moderate  pain  in  the  second,  and  potent  opioids
for  severe  pain  in  the  third  step.  Adjuvant  drugs  may  be
involved  in  all  steps.
In  a  retrospective  study  of  1229  patients  with  can-
cer  pain,  the  author  reports  that  the  analgesic  ladder  is
effective  in  71%.3 Many  patients  do  not  get  adequate  pain
relief.4,5
Factors  related  to  patients,  healthcare  institutions  and
regulatory  policies  on  drug  use  contribute  to  the  undertreat-
ment  of  pain.6,7 Many  patients  with  moderate  to  severe  pain
do  not  receive  analgesics  and  only  24%  of  those  with  severe
pain  are  medicated  with  a  potent  opioid.  In  one  study,  32%
of  patients  reported  that  the  discomfort  was  so  great  that
they  preferred  death.8 Despite  the  evolution  of  knowledge
about  pain,  more  than  80%  of  patients  with  advanced  can-
cer  suffer  from  pain.9 In  a  systematic  review,  the  authors
suggest  that  pain  is  undertreated  in  approximately  half  of
patients.10
Few  studies  have  proposed  an  alternative  to  the
WHO  ladder11 and  suggested  that  opioids  are  pre-
scribed  inappropriately.12 In  a  review,  the  authors  suggest
that  the  WHO  protocol  does  not  use  evidence-based
recommendations.13 Some  authors  criticize  the  restric-
tion  of  potent  opioids  for  the  third  step.14 In  a study
of  5084  patients,  56%  had  moderate  to  severe  pain  at
least  monthly.8 Better  pain  control  and  patient  satisfaction
could  be  obtained  with  the  use  of  potent  opioids  as  ﬁrst
medication.14
Because  of  these  controversies,  further  studies  are
needed.  The  aim  of  this  study  was  to  determine  whether
the  use  of  morphine  in  the  ﬁrst  step  of  the  WHO  ladder  can
improve  the  outcome.
i
tethod
odel
rospective  randomized  study.
articipants
fter  approval  by  the  Ethics  Committee  and  the  informed
ritten  consent  was  obtained,  the  effectiveness  of  mor-
hine  used  in  the  ﬁrst  step  of  the  WHO  ladder  was
nvestigated  in  patients  with  locally  advanced  and/or
etastatic  cancer.  Patients  with  difﬁculty  in  maintaining
linical  follow-up,  cognitive  impairment  and  previous  treat-
ent  with  opioids  were  excluded.  The  study  was  registered
t  clinicaltrials.gov  under  number  NCT01541124.
andomization,  intervention  and  evaluation
he  patients  were  divided  into  two  groups  with  the  use  of
nvelopes  containing  the  number  of  the  patient  and  the
roup  to  which  he  (she)  belonged.  Patients  were  included
n  the  sequence  by  allotment  in  the  visit.  G1  patients  were
reated  according  to  the  guidelines  of  the  WHO  analgesic
adder  and  started  on  the  ﬁrst  step,  with  paracetamol  1  g
very  six  hours  (maximum  dose  4 g/day);  in  the  second
tep,  codeine  (30  mg)  every  four  hours  (maximum  dose  of
60  mg/day);  and  morphine  10  mg  every  four  hours  in  the
hird  step.  G2  patients  received  morphine  10  mg  every  four
ours.  Whenever  indicated,  adjuvant  drugs  were  associated
o  the  treatment.
According  to  pain  intensity,  G1  patients  switched  drug
n  obedience  to  the  analgesic  ladder  and  G2  patients  had
djusted  the  dose  of  the  analgesic  drug.  The  need  for
alliative  cancer  therapy,  such  as  radiotherapy,  chemother-
py  or  hormone  therapy,  was  indicated  by  the  oncologist.
Pain  intensity  every  two  weeks  by  using  the  visual  ana-sfaction  with  treatment,  physical  capacity  as  assessed  by
he  Eastern  Cooperative  Oncology  Group  (ECoG)  index,16 and
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Evaluated for inclusion
(n: 150) 
Excluded (n: 90)
•Not attended to inclusion criteria (n: 90)
•Refused to participate (n: 0)
Randomized (n: 60)
Included in G1 (n: 30)
Treated (n: 30)
Not treated (n: 0)
Included in G2 (n: 30)
Treated (n: 30)
Not treated (n: 0)
Lost to follow-up (n: 6) Lost to follow-up (n: 1)
Evaluated (n: 24) Evaluated (n: 29)
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second  (G1:  1  ±  0.6,  G2:  0,  9  ±  0,  5,  p  =  0.8564),  third  (G1:
1.1  ±  0.5,  G2:  1.1  ±  0.5,  p  =  1.000),  fourth  (G:  1.2  ±  0,  4,
G2:  1.1  ±  0.5,  p  =  0.4203),  ﬁfth  (G1:  1.2  ±  0.6,  G2:  1.1  ±  0.4,
p  = 0.6234),  sixth  (G1:  1.2  ±  0.6,  G2:  1.20  ±  0.6,  p  =  0.7197)
Table  2  Pain  intensity  by  visual  analogue  scale  (cm;
mean ±  SD).Figure  1  C
eed  for  supplemental  analgesics  were  evaluated.  Adverse
ffects  were  recorded.  Follow-up  was  done  for  three  months
r  until  the  death  of  the  patient.
tatistical analysis
o  calculate  the  sample  size,  BioEstat  2.0  program  was  used.
he  mean  and  standard  deviation  of  another  similar  study
ere  used  as  reference.14 For  a  conﬁdence  level  of  95%  and  a
tudy  power  of  80%,  30  patients  per  group  (60  in  total)  were
equired.  For  the  statistical  analysis,  GraphPad  Prism  pro-
ram  was  used.  The  Student  t  test  to  compare  age,  weight
nd  height;  chi-square  test  for  patient  satisfaction,  need  for
omplementation  and  adverse  effects;  and  Mann--Whitney
est  for  pain  intensity,  quality  of  life  and  physical  function
ere  used.  p-Values  ≤0.05  were  considered  statistically  sig-
iﬁcant  and  the  results  were  expressed  as  mean  ±  SD.
esults
he  sequence  of  this  study  is  shown  in  the  diagram  (Fig.  1).
0  patients  were  included,  30  in  each  group.  By  reason  of
eath,  only  24  patients  from  G1  and  29  from  G2  completed
he  study.  The  groups  were  similar  with  respect  to  demo-
raphics  (sex,  age,  weight  and  height)  (Table  1).
The  most  common  locations  of  tumors  were  in  the  head
nd  neck  (G1:  22,  G2:  26),  with  the  same  region  for  pain
Table  1  Demographic  data  (mean  ±  SD).
G  1  G  2  p
Gender  M:F 25:5  27:3  0.7065a
Age  (years)  58.7  ±  12.4  57.5  ±  12.7  0.7071b
Weight  (kg)  59.8  ±  13.8  58.6  ±  13.0  0.7301b
Height  (cm)  166  ±  0.1  167  ±  0.1  0.7045b
G1, WHO ladder; G2, morphine in the 1st step.
a Fisher’ test.
b Student t test.RT  diagram.
G1:  21,  G2:  26).  The  most  frequent  type  of  pain  was
omatic  (G1:  27,  G2:  30).  There  was  no  signiﬁcant  differ-
nce  between  the  groups  with  respect  to  the  pain  duration
G1:  4  m;  G2:  3  m)  and  previous  use  of  paracetamol  (G1:  5,
2:  2),  dipyrone  (G1:  24,  G2:  24)  NSAIDs  (G1,  4  G2:  10),  tri-
yclic  antidepressants  (G1,  1  G2,  1),  anxiolytics  (G1:  1,  G2:
)  and  no  use  of  medication  (G1:  2,  G2:  1).
There  was  no  difference  in  the  need  for  comple-
entation  between  groups  on  the  third  (G1:  0;  G2:  11,
 = 0.5057),  fourth  (G1:  5;  G2:  9,  p  =  0.6696),  ﬁfth  (G1:  10,
2:  7,  p  =  0.5970),  sixth  (G1:  3,  G2:  7,  p  =  0.1966)  or  seventh
G1:  3,  G2:  5,  p  =  0.3576)  visit  (Student  t  test).  There  was
o  difference  in  pain  intensity  (Table  2) or  quality  of  life
Table  3).  There  was  no  difference  in  physical  capacity
n  the  ﬁrst  (G1:  0.7  ±  0.6,  G2:  0.8  ±  0.6,  p  =  0.4430),Follow-up  G  1  G  2  p
1st  visit 5.8  ±  0.4a 5.8  ±  0.4a 0.5267
2nd week 4.6  ±  2.3a 4.6  ±  2.6a 0.9579
4th week  4.9  ±  2.1a 4.2  ±  2.3a 0.2019
6th week  3.7  ±  2.6b 3.7  ±  1.9b 0.9548
8th week  2.9  ±  2.6c 3.8  ±  2.5c 0.2307
10th week  2.5  ±  1.9e 3.4  ±  2.2c 0.1185
12th week  2.3  ±  2.1f 2.9  ±  2.5d 0.3400
G1, WHO  ladder; G2, morphine in the 1st step.
Student t test.
a 30.
b 29.
c 28.
d 27.
e 24.
f 23.
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Table  3  Quality  of  life.
Follow-up  G1  G2  p
1st  visit  92.2  ±  11.7a 93.0  ±  10.5a 0.7816
4th week  88.3  ±  11.2a 89.7  ±  13.1a 0.6511
8th week  88.7  ±  13.2b 92.0  ±  10.4b 0.3003
12th week  91.1  ±  13.3d 91.0  ±  12.8c 0.9641
G1, WHO ladder; G2, morphine in the 1st step.
Student t test.
a 30.
b 28.
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or  seventh  (G1:  1.2  ±  0.5,  G2:  1.4  ±  0.7,  p  =  0443)  visit
(Mann--Whitney).  Satisfaction  with  treatment  was  similar
in  both  groups:  on  the  second  (G1:  20,  G2:  24,  p  =  0.5275),
third  (G1:  22,  G2:  27,  p  =  0.3288),  fourth  (G1:  22  G2:  28,
p  =  0.1056),  ﬁfth  (G1:  26,  G2:  26,  p  =  1),  sixth  (G1:  24,  G2:  29,
p  =  1)  and  seventh  (G1:  24,  G2:  28,  p  =  1)  visit  (chi-square).
There  was  statistically  signiﬁcant  difference  between
groups  in  the  second  visit  to  nausea  (G1:  5,  G2:  15,
p  =  0.0088),  constipation  (G1:  14,  G2:  25,  p  =  0.0071),  dizzi-
ness  (G1,  6,  G2:  14,  p  =  0.0376)  and  drowsiness  (G1:  13,  G2:
27,  p  =  0.0005)  and  there  was  also  a  statistically  signiﬁcant
difference  in  the  third  visit  to  drowsiness  (G1:  17,  G2:  25;
p  =  0.05),  always  with  greater  frequency  in  G2  (chi-square).
Discussion
In  this  study,  there  was  a  reduction  in  pain  intensity  in  the
two  groups,  which  suggests  that  the  techniques  are  effec-
tive.  In  another  study,  patients  receiving  potent  opioids  had
better  pain  control  and  greater  satisfaction  than  the  con-
ventional  group,  but  with  more  adverse  effects.11
It  is  possible  that  the  combination  of  paracetamol  and
morphine  resulted  in  better  analgesic  effect.  In  other
studies,  the  combination  of  potent  opioids  and  non-
opioids  resulted  in  better  control  of  pain.12,14 However,  in
one  study  half  the  patients  previously  treated  with  the
d
c
s
Table  4  Morphine  dose  (mg/day).
Visits  G1  
1st  visit  --a
2nd week  --a
3rd week  71.54  ±  28.82a
4th week  75.00  ±  29.56b
5th week 80.00  ±  43.79c
6th week  69.41  ±  43.08e
7th week 79.38  ±  53.60f
G1, with ladder; G2, without ladder.
Student t test.
a 30.
b 29.
c 28.
d 27.
e 24.
f 23.239
ombination  of  paracetamol  with  a  potent  opioid  also
btained  pain  control  without  paracetamol;  a  substantial
umber  of  patients  discontinued  the  use  of  this  agent,
ecause  of  the  inconvenience  of  swallowing  so  many  medi-
ations,  and  still  maintained  control  of  pain.17,18 According
o  these  data,  G2  patients  did  not  require  very  large  doses
f  morphine  for  pain  relief,  even  without  paracetamol.  For
atients  with  moderate  to  severe  pain  who  previously  did
ot  use  opioids,  a  lower  initial  dose  of  morphine  (15  mg/day)
ay  be  effective  and  well  tolerated.19
There  was  no  worsening  of  quality  of  life  and  physical
apacity  during  the  course  of  this  study,  but  this  did  not
eﬂect  the  negative  impact  of  the  disease.  In  another  study,
lthough  patients  receiving  potent  opioids  have  obtained
etter  pain  control,  the  quality  of  life  and  physical  function
radually  deteriorated.14
In  this  study  there  was  no  difference  in  patient  satisfac-
ion,  which  is  an  important  form  of  assessment.  Another
mportant  point  is  the  incidence  of  adverse  effects.  In
nother  study,  patients  receiving  potent  opioids  were  more
atisﬁed,  but  had  more  adverse  effects.11 There  was  a  lower
ncidence  of  nausea  in  patients  with  conventional  treatment
nd  in  whom  the  doses  of  opioids  were  adjusted  according
o  the  severity  of  pain.14 In  this  study,  a  higher  incidence  of
dverse  effects  occurred  when  morphine  was  the  ﬁrst  drug
dministered,  which  is  in  agreement  with  the  validation  of
he  WHO  ladder.3 However,  no  impairment  of  quality  of  life
as  observed  in  the  second  and  third  visits,  which  supports
he  use  of  morphine  as  a  ﬁrst  drug.  Effects  such  as  nausea,
omiting  and  constipation  can  be  managed  with  prophylactic
ntiemetics  and  laxatives.  It  is  possible  that  the  incidence  of
rowsiness  and  dizziness  was  comparable  to  that  observed
ith  the  WHO  ladder  if  the  G2  patients  had  received  lower
oses  of  morphine  and  in  association  with  paracetamol  or
ipyrone.  The  initial  dose  of  morphine  in  G2  was  ﬁxed  for
ll  patients,  which  may  have  contributed  to  the  higher  inci-
ence  of  adverse  effects.  The  individualization  of  the  initial
ose  based  on  the  intensity  of  pain,  with  gradual  increases,
an  reduce  the  incidence  of  adverse  effects.
The  motivation  for  this  study  was  the  small  number  of
tudies  investigating  an  option  to  the  WHO  ladder  for  the
G2  p
60.00  ±  0a --
67.33  ±  32.48a --
80.00  ±  41.77a 0.5110
80.52  ±  50.15b 0.5986
87.86  ±  52.09c 0.5986
93.21  ±  59.69c 0.1598
98.15  ±  58.84d 0.3024
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140  
reatment  of  cancer  pain.  About  30%  of  patients  have  moder-
te  to  severe  pain  and  one  reason  may  be  the  inappropriate
rescription  of  opioids.12
The  sample  was  obtained  in  two  years  and  six  months
ecause  of  the  difﬁculty  of  ﬁnding  patients  who  attended  to
he  inclusion  criteria.  In  a  similar  study,  the  authors  failed  to
nclude  the  number  of  the  calculated  sample.11 In  another
tudy,  patients  with  mild  to  moderate  pain  were  included
nd  would  be  excluded  only  if  they  were  using  potent  opi-
ids,  and  this  facilitated  the  allocation.14 It  is  believed  that
he  sample  size  of  this  study  is  sufﬁcient  to  reﬂect  the  effect
f  the  medications  according  to  WHO  and  of  the  use  of  mor-
hine  as  a  ﬁrst  medication.  The  patients’  clinical  conditions
ake  it  difﬁcult  to  implement  the  protocol  in  this  group  with
dvanced  cancer.
In  this  study,  high  incidence  of  head  and  neck  tumors
as  diagnosed,  unlike  other  studies,11,14 but  all  patients
ttended  to  the  inclusion  criteria  because  the  cancer  was
lready  in  an  advanced  stage  at  diagnosis,  with  moderate
ain,  and  never  previously  treated  with  opioids.  In  one  study,
wo  out  of  three  patients  with  head  or  neck  cancer  had  pain
or  six  months  before  diagnosis.20 The  most  commonly  used
ainkiller  before  the  ﬁrst  consultation  was  dipyrone,  and  in
nother  study  anti-inﬂammatory  were  the  drugs  most  often
sed.11
It  can  be  concluded  that  both  methods  of  treating  pain
n  advanced  cancer  patients  are  comparable,  with  the
ifference  that  patients  receiving  morphine  as  ﬁrst  med-
cation  have  more  adverse  effects  on  the  beginning  of
reatment.  For  selected  patients  with  severe  pain,  the  use
f  a  potent  opioid  may  be  a  more  appropriate  measure.
he  main  limitation  of  this  study  is  its  impossibility  of
he  use  of  a  double-blind  design.  More  studies  are  rec-
mmended  to  evaluate  options  for  the  analgesic  ladder
Table  4).
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